Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARγ activation by troglitazone

Abstract

Over-expression of P-glycoprotein (P-gp), an ATP-dependent drug efflux pump, represents one of the major mechanisms that contribute to multidrug resistance (MDR) in cancer cells. This study examined the effects of troglitazone, a ligand of peroxisome proliferator-activated receptor gamma (PPARγ), on P-gp-mediated MDR in SGC7901/VCR cells (a vincristine-resistant human gastric cancer cell line). The expression of P-gp was detected by RT-PCR and Western blotting, respectively. The SGC7901/VCR cells were treated with 0.1 mg/L vincristine (VCR) alone or in combination with 1, 5, 10 μmol/L troglitazone for 24 h. PPARγ was measured by electrophoretic mobility shift assay (EMSA). The intracellular concentration of Rhodamine123 (Rh123, a fluorescent P-gp substrate) was assayed to evaluate the activity of P-gp. The cell cycle and apoptosis were measured by flow cytometry. The results showed that the P-gp was increasingly expressed in SGC7901, BGC823 and SGC7901/VCR cells in turn, suggesting that MDR in the SGC7901/VCR cells was mediated by the increased expression of P-gp. In the SGC7901/VCR cells, the expression level of total PPARγ was increased, however, the protein level and activity of PPARγ in the nuclei of cells decreased significantly. Troglitazone elevated the PPARγ activity in SGC7901/VCR cells in a dose-dependent manner. Troglitazone decreased the P-gp expression and markedly enhanced the accumulation of Rh123 in SGC7901/VCR cells in a dose-dependent manner. We also found that troglitazone significantly increased the percentage of SGC7901/VCR cells in the G₂/M phase and decreased the cell percentage in G₁ and S phase in a dose-dependent manner. Troglitazone significantly increased the apoptotic rate of SGC7901/VCR cells treated by VCR or ADR in a dose-dependent manner. It was concluded that P-gp-overexpressed SGC7901/VCR cells have minor endogenous PPARγ activity. Elevation of the PPARγ activity by troglitazone can reverse P-gp-mediated MDR via down-regulating the expression and activity of P-gp in SGC7901/VCR cells. It was suggested that troglitazone can dramatically enhance the sensitivity of P-gp-mediated MDR cancer cells to chemotherapeutic agents.

Keywords

multidrug resistance / peroxisome proliferator-activated receptor gamma / P-glycoprotein / troglitazone / SGC7901/VCR cells

References

[1] PisaniP., ParkinD.M., BrayF., et al.. Erratum: estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer, 1999, 83(6): 870-873

[2] ZhouJ., LiuM., AnejaR., et al.. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res, 2006, 66(1): 445-452

[3] LageH.. Molecular analysis of therapy resistance in gastric cancer. Dig Dis, 2003, 21(4): 326-338

[4] LeungW.K., BaiA.H.C., ChanV.Y.W., et al.. Effect of peroxisome proliferator activated receptor γ ligands on growth and gene expression profiles of gastric cancer cells. Gut, 2004, 53(3): 331-338

[5] KrishnanA., NairS.A., PillaiM.R.. Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med, 2007, 7(6): 532-540

[6] BonofiglioD., AquilaS., CatalanoS., et al.. Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Mol Endocrinol, 2006, 20(12): 3083-3092

[7] SunX., MuR., ZhouY., et al.. 1990–1992 mortality of stomach cancer in China. Zhonghua Zhongliu Zazhi (Chinese), 2002, 24(1): 4-8

[8] SunX.D., MuR., ZhouY.S., et al.. Analysis of mortality rate of stomach cancer and its trend in twenty years in China. Zhonghua Zhongliu Zazhi (Chinese), 2004, 26(1): 4-9

[9] OzbenT.. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett, 2006, 580(12): 2903-2909

[10] SzakácsG., PatersonJ.K., LudwigJ.A., et al.. Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 2006, 5(3): 219-234

[11] GottesmanM.M., FojoT., BatesS.E.. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer, 2002, 2(1): 48-58

[12] NotarbartoloM., CervelloM., DusonchetL., et al.. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-gp, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett, 2002, 180(1): 91-101

[13] LiM., LeeT.W., MokT.S., et al.. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem, 2005, 96(4): 760-774

[14] KliewerS.A., UmesonoK., NoonanD.J., et al.. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature, 1992, 358(6389): 771-774

[15] MarcusS.L., CaponeJ.P., RachubinskiR.A.. Identification of COUP-TFII as a peroxisome proliferator response element binding factor using genetic selection in yeast: COUP-TFII activates transcription in yeast but antagonizes PPAR signaling in mammalian cells. Mol Cell Endocrinol, 1996, 120(1): 31-39

[16] HeinäniemiM., CarlbergC.. Screening for PPAR responsive regulatory modules in cancer. PPAR Res, 2008, 2008: 749073-749080

[17] ChenG.G., LeeJ.F., WangS.H., et al.. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci, 2002, 70(22): 2631-2646

[18] GuptaR.A., PolkD.B., KrishnaU., et al.. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem, 2001, 276(33): 31059-31066

[19] SmythM.J., KrasovskisE., SuttonV.R., et al.. The drug efflux protein, P-gp, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A, 1998, 95(12): 7024-7029

[20] UllahM.F.. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev, 2008, 9(1): 1-6

[21] MondenN., AbeS., HishikawaY., et al.. The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy. Int J Surg Investig, 1999, 1(1): 3-10

This project was supported by grants from Natural Sciences Foundation of Hubei Province (No. 2007ABA065) and Science and Technology Key Project of Health Bureau of Hubei Province (No.JX1B006).